SHANGHAI – Ascletis Pharmaceuticals Co. Ltd. – China's answer to Gilead Sciences Inc. with its own curative HCV treatments in the clinic here – has just received its second tranche of financial backing in almost as many months, but this time around the funds are coming from investment bank, Goldman Sachs.